Rosenberg N K, Rosenberg R
Psychological Department, University Hospital of Aarhus, Denmark.
Scand J Psychol. 1994 Sep;35(3):254-62. doi: 10.1111/j.1467-9450.1994.tb00949.x.
Forty Danish panic disorder patients participating in a placebo controlled study of alprazolam and imipramine (The Cross National Collaborative Panic Study, Phase II) were followed up by a telephone interview three years later, with essentially the same battery of evaluation procedures applied at baseline, end of study, and follow-up. The main finding was that panic disorder is a chronic disorder, but fluctuating in form and severity in the course of time. Twenty-five percent of the patients no longer fulfilled the DSM-III criteria for panic disorder, but had substantial disability due to a variety of symptoms, including panic attacks at infrequent rate, generalized anxiety symptoms, affective symptoms, and phobic avoidance behavior. Nearly three fourths of the patients were under treatment at follow-up. Benzodiazepines were the drugs most often prescribed, usually in combination with supportive psychotherapy. It was concluded that the different types of treatment offered were insufficient. Variables predicting panic disorder or substantial disability at 3-years follow-up were few.
四十名参与阿普唑仑和丙咪嗪安慰剂对照研究（跨国协作惊恐研究，第二阶段）的丹麦惊恐障碍患者，在三年后接受了电话随访，在基线、研究结束时和随访时采用了基本相同的一系列评估程序。主要发现是惊恐障碍是一种慢性疾病，但在病程中形式和严重程度会波动。25%的患者不再符合DSM-III惊恐障碍标准，但由于各种症状而有严重残疾，包括偶尔发作的惊恐发作、广泛性焦虑症状、情感症状和恐惧回避行为。近四分之三的患者在随访时正在接受治疗。苯二氮䓬类药物是最常处方的药物，通常与支持性心理治疗联合使用。得出的结论是所提供的不同类型治疗是不足的。在三年随访中预测惊恐障碍或严重残疾的变量很少。
